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OBJECTIVES The purpose of this study was to evaluate the prevalence and prognostic importance of lower
extremity arterial disease (LEAD) in patients with multivessel coronary artery disease.
BACKGROUND The presence of clinically evident LEAD increases the risk of death in patients with known
coronary artery disease. Because studies have lacked noninvasive measures of subclinical
LEAD, the true prognostic importance of lower extremity atherosclerosis in this population
has probably been underestimated.
METHODS Ankle blood pressures were measured in 405 consecutive patients with angiographically
documented multivessel coronary disease from seven Bypass Angioplasty Revascularization
Investigation (BARI) sites and a parallel study site within 3 years of enrollment. Lower extremity
arterial disease was defined as an ankle/arm systolic blood pressure ratio of 0.90 or less.
RESULTS Among patients studied, 69 (17%) had LEAD. These patients were more likely to be current
smokers, treated for diabetes, older and present with unstable angina compared with patients
without LEAD. Among patients who underwent coronary arterial bypass grafting, major
complications occurred in 2.8% of those without LEAD compared with 20.7% of those with
LEAD (p 5 0.002). Five-year mortality rates were similar for symptomatic LEAD (14%) and
asymptomatic LEAD (14%). Patients without LEAD had a 3% mortality. After adjusting for
baseline differences, the relative risk of death was 4.9 times greater for patients with LEAD
compared with those without (95% confidence interval [CI]: 1.8, 13.4, p , 0.01).
CONCLUSIONS Patients with LEAD have a significantly higher risk of death than patients without LEAD,
regardless of the presence of symptoms. An abnormal ankle/arm index is a strong predictor of
mortality and can be used to further stratify risk among patients with multivessel coronary artery
disease. (J Am Coll Cardiol 1999;34:716–21) © 1999 by the American College of Cardiology
Evidence of peripheral atherosclerosis is strongly associated
with long-term mortality in patients with coronary artery
disease (1,2). Although these studies have demonstrated the
importance of peripheral atherosclerosis in a population
diagnosed with coronary disease, both studies lacked stan-
dard, noninvasive evidence of subclinical disease. Thus, the
prognostic importance of peripheral atherosclerosis may
have been underestimated.
It is well documented that the prevalence of coronary
artery disease in patients with lower extremity arterial
disease (LEAD) is high (3–5) and that the prevalence of
LEAD is also increased in patients with acute coronary
artery disease (1,6,7). In fact, cardiovascular and cerebro-
vascular disease and death occur more often in patients with
LEAD (8,9). Criqui et al. (10) noted a high prevalence of
cardiovascular events among those with peripheral arterial
disease, even when analysis was controlled for the presence
of risk factors such as smoking, diabetes, age and gender.
Furthermore, these authors reported a four-fold excess risk
of mortality in those with peripheral artery disease regard-
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less of other cardiovascular risk factors. Similarly, among
1,440 subjects presenting with intermittent claudication
studied by Boyd (11), nonfatal myocardial infarction (MI)
occurred within five years in 20%.
Follow-up studies of patients with intermittent claudica-
tion report a higher mortality rate than that in the general
population (8). However, symptoms of intermittent claudi-
cation alone have repeatedly been found to underestimate
the prevalence of LEAD (5,10,12). Therefore, ankle blood
pressure measurement, a simple, inexpensive and highly
accurate method for detecting LEAD, has been used in
many large epidemiologic studies. Atherosclerotic disease of
the large vessels of the leg can be easily detected by
obtaining an ankle blood pressure using a standard blood
pressure cuff and a Doppler probe (10,13,14). Compared
with angiography, an abnormal ankle/arm index (AAI) has
been shown to have a sensitivity and specificity of 96% or
higher (8).
The purpose of this study was to assess the prevalence and
prognostic importance of LEAD in patients with angio-
graphically documented coronary artery disease. Patients
evaluated were enrolled in the Bypass Angioplasty Revas-
cularization Investigation (BARI) study, and LEAD was
evaluated using the AAI. Risk factors for LEAD are
presented, and mortality rates are compared between those
with and without LEAD.
METHODS
Study population. The development and implementation
of BARI have been fully described elsewhere (15,16). In
brief, BARI is a multicenter study composed of both a
randomized trial and two registries. The goal is to compare
percutaneous transluminal coronary angioplasty (PTCA) to
coronary artery bypass grafting (CABG) as treatment for
coronary artery disease. Patients eligible for randomization
had angiographically documented multivessel coronary dis-
ease with clinically severe angina or objective evidence of
ischemia and were suitable candidates for CABG and for
PTCA. Patients with a prior coronary revascularization
procedure, single-vessel coronary disease, primary congeni-
tal, valvular or myocardial heart disease and of the ages less
than 17 or greater than 80 years were excluded. Eligible
patients who did not consent to randomization as well as a
random sample of patients who were excluded based on
angiographic grounds were followed in one of two registries.
Patients in the randomized study were randomly assigned to
CABG or PTCA, and patients in the two registries, in
conjunction with their physicians, selected either CABG,
PTCA or medical therapy. Between 1988 and 1993, 18
participating clinical centers enrolled 4,261 patients, of
whom 1,829 were randomized, 2,010 were eligible patients
who refused randomization and 422 were angiographically
excluded patients. An additional 112 patients were enrolled
into a parallel study conducted in Prague, Czech Republic;
these patients consisted of 79 randomized, 11 eligible but
not randomized and 22 angiographically excluded patients.
Patients enrolled in the LEAD substudy came from all
components of BARI including the randomized trial, the
eligible not randomized registry, the angiographically ex-
cluded registry and the Prague parallel study. The patient
population and, therefore, the baseline and procedural data
presented in this paper are different from data presented in
other BARI papers (2,16).
Ankle blood pressures were measured within three years
of enrollment between December 1992 and March 1994 in
405 consecutive patients from seven participating BARI
sites and from the Prague parallel study. All subsets of
patients have been followed for an average of 5.4 years from
study entry. It is important to note that most participants
were enrolled into the LEAD substudy approximately three
years after the start of the BARI trial. This population
consists of BARI trial participants who are three-year
survivors. Thus, events begin for patients in the LEAD
substudy at approximately year three.
Certification. Participating BARI centers followed a stan-
dard protocol for obtaining ankle blood pressures. Central
training was provided and at least one observer from each
participating clinical site was certified. Certified observers
provided additional training at their clinical site as neces-
sary.
Protocol. During follow-up clinic visits, patients were
placed in a supine position for at least 5 min. The systolic
blood pressure of the right brachial artery and the posterior
tibial artery of both ankles were measured using a standard
blood pressure cuff and a Parks Model 841-A pocket
Doppler probe (Parks Medical Electronics Inc., Aloha,
Oregon). Systolic blood pressure was recorded as the cuff
pressure when Doppler flow became detectable. Each blood
pressure was performed twice and results were averaged.
The ratio of ankle to arm systolic blood pressure was
calculated for each leg and the lowest ratio (right leg/arm or
left leg/arm) was recorded as the AAI. Based on validity
studies for using this technique, lower extremity arterial
disease was defined as an AAI of 0.09 or below.
Statistical analysis. Baseline characteristics and follow-up
events for patients with LEAD were compared with those
for patients without LEAD. Baseline comparisons were
Abbreviations and Acronyms
AAI 5 ankle/arm index
BARI 5 Bypass Angioplasty Revascularization
Investigation
CABG 5 coronary arterial bypass grafting
CI 5 confidence interval
LEAD 5 lower extremity arterial disease
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary
angioplasty
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made using chi-square statistics for categorical variables and
Student t tests or Wilcoxon nonparametric statistics for
continuous variables. Due to the small number of in-
hospital complications, Fisher’s exact tests were used to
compare the in-hospital complication rates for those with
and without LEAD. Survival curves were estimated by the
Kaplan-Meier method (18) and were compared with the log
rank test. A multivariate Cox proportional hazards model
(19) was used to test the independent association between
low AAI and mortality while adjusting for covariates that
are related to AAI and mortality in this population. Vari-
ables included in this model were gender, history of smok-
ing and a comorbidity scale accounting for history of MI,
hypertension, congestive heart failure and treated diabetes
(age was also considered in the model but it had no
significant influence on mortality or on the relative risk of
LEAD after controlling for the other variables listed). To
evaluate the prognostic importance of LEAD with accom-
panying symptoms of intermittent claudication, a three way
comparison involving symptomatic LEAD, asymptomatic
LEAD and no LEAD was considered using Kaplan-Meier
survival curves and the Cox regression analysis. Symptom-
atic LEAD was defined as having an AAI of 0.90 or less and
reporting accompanying symptoms of intermittent claudi-
cation at baseline. Statistical significance was defined as a p
value of 0.05 or less.
RESULTS
The population analyzed consisted of 405 patients: 302
(75%) randomized, 57 (14%) eligible but not randomized
and 46 (11%) angiographically excluded patients. Three
hundred sixteen (78%) patients were from the seven partic-
ipating BARI sites and 89 (22%) were from the Prague
parallel study. The distribution of the AAI measurements is
shown in Figure 1. The median AAI was 1.0 with a range
of 0.39 to 1.4. Of the 405 patients evaluated, 69 (17%) had
an AAI of 0.9 or less.
Baseline characteristics for patients with and without
LEAD are shown in Table 1. Patients with LEAD tended
to be older, were more likely to have a history of treated
diabetes, were more often current smokers and more often
presented with symptoms of unstable angina. The propor-
tion of patients with a history of hypertension and hyper-
cholesterolemia was similar between those with LEAD and
those without LEAD. The baseline angiographic character-
istics between those with and without LEAD were quite
similar with respect to the number of diseased vessels, the
number of significant lesions and mean ejection fraction.
Vascular disease other than coronary artery disease in the
LEAD substudy patients at baseline is shown in Table 2. In
general, other vascular disease was more prevalent among
Figure 1. Distribution of the ankle/arm index measures in the
LEAD substudy of BARI.
Table 1. Baseline Characteristics and Medical History
LEAD
p Value
No
(N 5 336)
Yes
(N 5 69)
Age (mean) 57 61 , 0.001
Age $65 (%) 20 36 0.004
Male (%) 84 75 0.102
Education
Grade school 23 32
High school 36 41
Above high school 41 28 0.095
History of diabetes (%) 15 22 0.14
Treated diabetes (%) 9 18 0.019
History of hypertension (%) 40 52 0.066
Current smoker (%) 17 29 0.024
History of hypercholesterolemia
(%)
38 49 0.093
Unstable angina (%) 32 55 0.001
Angiographic
Number of diseased vessels
(mean)
2.2 2.3 0.90
Triple vessel disease (%) 33 33 0.95
Number of total lesions (mean) 5.5 6.0 0.13
Number of significant lesions
(mean)
3.1 3.0 0.77
Ejection fraction (mean) 59.5 59.0 0.76
Presence of class C lesions (%) 43 48 0.40
LEAD 5 lower extremity arterial disease.
Table 2. Other Vascular Disease at Baseline
LEAD
p value
No
(N 5 336)
Yes
(N 5 69)
Stroke/TIA (%) 2 10 0.002
Carotid bruit (%) 1 20 , 0.001
Carotid disease on ultrasound
(%)
0.3 7 , 0.001
History of MI (%) 56 48 0.023
History of CHF (%) 2 6 0.092
Reporting intermittent
claudication at baseline (%)
0.9 31 , 0.001
CHF 5 congestive heart failure; MI 5 myocardial infarction; TIA 5 transient
ischemic attack.
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those with LEAD compared with those without LEAD.
Thirty-one percent of the LEAD patients reported symp-
toms of intermittent claudication. Those with LEAD were
more likely to have a history of stroke/TIA and evidence of
carotid artery disease. However, a history of MI was more
prevalent among those without LEAD. Finally, in this
study, the proportion of patients with LEAD was similar
within each of the three BARI study groups, within the
U.S. and Prague and among the patients who received
PTCA, CABG and medical therapy (p . 0.30 for all three
comparisons).
One hundred ninety-eight patients in the LEAD study
underwent angioplasty. Patients with LEAD had fewer
lesions intended as well as fewer lesions attempted (Table
3). Among attempted lesions, there was no difference in
angioplasty success rates between the two groups. There
were no in-hospital deaths following the initial PTCA
procedure in the LEAD study. Patients with and without
LEAD had similar rates of major in-hospital complications
(a combined end point of MI, stroke and coma) as well as
similar rates of in-hospital emergency revascularization.
Among the 171 patients who underwent bypass surgery,
major lesions were bypassed equivalently in both LEAD
and non-LEAD groups (Table 3). It is interesting to note
that patients with LEAD were more likely to have a
calcified aorta (p 5 0.017). Following the initial bypass
surgery procedure, patients with LEAD had significantly
higher rates of in-hospital major complications compared
with those without LEAD (MI, stroke or coma: 20.7% vs.
2.8%; p 5 0.0019); in the group of patients with LEAD,
three patients had an MI, three had a stroke and none had
a coma. There were no in-hospital deaths or emergency
revascularizations following the initial CABG procedure in
either group. Results were consistent across all strata when
the analysis of complications was stratified by study group
(randomized vs. registry) and by country (U.S. vs. Czech
Republic).
For PTCA and CABG procedures combined, subsequent
revascularization rates were 29% for both those with and
without LEAD. When focusing on the PTCA group alone,
repeat procedure rates were the same for those with LEAD
versus those without LEAD (29%), but those with LEAD
were slightly more likely to have subsequent CABG (22%
LEAD, 19% no LEAD) and less likely to have subsequent
PTCA (19% LEAD and 22% no LEAD).
During follow-up procedures, patients with LEAD had
significantly lower survival rates compared with patients
without LEAD (Figure 2). Five-year cumulative mortality
Table 3. Procedural Characteristics and Outcome
LEAD
p Value
No
(N 5 163)
Yes
(N 5 35)
PTCA
Number of intended lesions (mean) 2.3 2.0 0.029
Number of attempted lesions (mean) 2.1 1.7 0.021
PTCA intended lesion success
All lesions (%) 61 65
Some lesions (%) 31 32
No lesions (%) 8 3 0.63
Major event (MI/stroke/coma) (%) 1.2 0.0 1.0
Emergency revascularization (%) 3.7 5.7 0.58
CABG (N 5 142) (N 5 29)
Calcified aorta (%) 2 14 0.017
Number of grafts (mean) 2.8 2.8 0.92
IMA use (%) 84 76 0.31
All intended vessels grated (%) 85 79 0.43
Major event (MI/stroke/coma) (%) 2.8 20.7 0.0019
Emergency revascularization (%) 0.0 0.0 —
CABG 5 coronary artery bypass graft; PTCA 5 percutaneous transluminal coronary angioplasty.
Figure 2. Kaplan-Meier survival curves for patients with and
without LEAD in the LEAD substudy of BARI.
719JACC Vol. 34, No. 3, 1999 Burek et al.
September 1999:716–21 PVD in Patients with Coronary Disease
rates were 14% for patients with LEAD and 3% for patients
without LEAD (p , 0.001). The unadjusted relative risk of
death for patients with LEAD compared with those with-
out LEAD was 5.2 (95% confidence interval [CI] 5 1.9,
13.8). After adjusting for baseline differences between the
two groups, the relative risk of death was 4.9 times greater
for patients with LEAD compared with those without (95%
CI 5 1.8, 13.4, p 5 0.0022). Evaluating the symptomatic
and asymptomatic LEAD groups separately, five-year mor-
tality rates were 14% among those with symptomatic
LEAD (n 5 21) and 14% for those with asymptomatic
LEAD (n 5 48). In multivariate analysis, there was no
significant difference between the symptomatic and asymp-
tomatic LEAD groups regarding risk of death (p 5 0.88).
Compared with patients without LEAD, the adjusted
relative risk of death was 4.4 (95% CI: 0.92, 21.4) for
patients with symptomatic LEAD and 5.1 (95% CI: 1.7,
15.6) for patients with asymptomatic LEAD.
DISCUSSION
When using an ankle/arm systolic blood pressure ratio of
0.90 or less to define LEAD in patients with coronary
disease, we found a relative risk of mortality 4.9 times higher
for patients with LEAD compared with those without
LEAD. This risk of mortality is substantially higher than
that found in previous studies of patients with coronary
artery disease (1,2). The greater relative risk found here is
likely due to a more accurate measure of subclinical periph-
eral vascular disease with the use of the AAI. The striking
association between the presence of LEAD and an in-
creased incidence of major complications following bypass
surgery was also of clinical significance. This association was
also noted in the full BARI randomized and registry
populations when peripheral atherosclerosis was identified
by questionnaire (20).
This study supports the use of the AAI measurement for
detection of asymptomatic LEAD even in patients with
advanced atherosclerosis. Patients with LEAD had higher
mortality rates regardless of the presence or absence of
symptoms. Consequently, many patients who are at in-
creased risk could easily be identified if ankle blood pres-
sures were a routine part of the physical exam in patients
being evaluated for coronary disease. A lack of symptoms in
many of these patients is likely due to the inherent low
physical activity of patients with existing coronary athero-
sclerosis and low activity level of older adults in general.
The AAI is simple, inexpensive and associated with no
risk to patients. Thus, the use of this measure with other
clinical cardiovascular risk assessment strategies can enhance
primary and secondary risk management. This noninvasive
diagnostic tool has been underutilized as a risk-stratification
tool in routine practice. A compelling argument for the
routine use of the AAI is the fact that among the 69 patients
with LEAD, 21 were symptomatic and 48 were asymptom-
atic at baseline. Therefore, if the ankle blood pressures had
not been done, 48 participants (70%) would not have had
their lower extremity disease identified. Our data indicate
that the risk associated with LEAD is similar whether or
not symptoms of intermittent claudication are present. Of
the 69 patients with LEAD, 35 (51%) had no other
evidence of noncoronary atherosclerosis (based on the vari-
ables presented in Table 2). Thus, there are a relatively large
number of patients in whom an abnormal ankle blood
pressure would provide the only evidence of peripheral
atherosclerosis.
At baseline, patients with LEAD were more likely to be
current smokers, treated diabetic patients, older and pre-
senting with unstable angina compared with patients with-
out LEAD. The prevalence of LEAD among older persons
with multivessel coronary artery disease is in accordance
with previous studies (21,22). From a public health perspec-
tive, the high prevalence of LEAD in the older population
is important. As the percentage of older people in the
population increases, disease burden will increase the cost of
medical care. In addition, coronary atherosclerosis is corre-
lated with LEAD, and LEAD has been demonstrated to
correlate with acute coronary artery disease (10). It is not
surprising that this study, like other atherosclerotic studies,
suggests that LEAD is strongly associated with cardiovas-
cular risks, diabetes mellitus and current smoking (1,3,5,10).
It is important for clinicians to provide treatment to slow
the atherosclerotic process by eliminating or reducing mod-
ifiable risk factors. This should include a concerted effort to
minimize disease progression with smoking cessation, reg-
ular exercise and control of glucose and lipid abnormalities.
Angiographic baseline comparisons were similar between
those with and without LEAD. However, other vascular
disease was associated with LEAD. A history of stroke or
TIA and carotid vascular disease was present significantly
more often among those with LEAD. These findings
support the suggestion that peripheral atherosclerosis mir-
rors the general atherosclerotic process ongoing in the
coronary and intracerebral vessels (23).
In summary, patients with coronary artery disease and
associated LEAD are at significantly higher risk of death
than patients without LEAD. Risk is significantly elevated,
even when LEAD is asymptomatic. The simple nature of
the AAI, a noninvasive diagnostic test, provides an inex-
pensive way to provide the clinician with additional infor-
mation for cardiovascular risk stratification, including risk of
complications during bypass surgery.
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